Does Network Health Cover Eliquis? A Complete Coverage Guide

What Is Eliquis and Why Does Coverage Matter?

Eliquis (apixaban) is an oral anticoagulant that blocks factor Xa to reduce the risk of stroke, deep vein thrombosis (DVT), and pulmonary embolism (PE). The FDA first approved it in December 2012 for reducing stroke risk in nonvalvular atrial fibrillation, and subsequent approvals expanded its indications to include DVT/PE treatment and prophylaxis after hip or knee replacement surgery [1].

Coverage decisions matter because Eliquis carries a retail price of roughly $600, $700 per 30-day supply in the United States. Unlike warfarin, which costs a few dollars per month, Eliquis has no FDA-approved generic as of early 2025 [2]. That price gap makes formulary placement the single biggest factor in determining whether a patient can afford continuous anticoagulation.

Why Continuous Anticoagulation Cannot Be Interrupted

Stopping anticoagulation abruptly raises stroke risk dramatically. In the ARISTOTLE trial (N=18,201), patients with atrial fibrillation assigned to apixaban experienced a 21% relative reduction in stroke or systemic embolism compared with warfarin (1.27% vs. 1.60% per year; P<0.001) [3]. Patients who discontinued therapy without a clinical reason lost that protection immediately. The American Heart Association and American College of Cardiology joint guideline on atrial fibrillation states: "Anticoagulation should not be interrupted for minor procedures, and if interruption is necessary, the shortest possible window should be used" [4].

What Conditions Qualify for Coverage?

Network Health, like most commercial and Medicare insurers, follows FDA-labeled indications when adjudicating Eliquis claims. Covered indications generally include:

• Nonvalvular atrial fibrillation stroke prevention
• Acute DVT and PE treatment
• Reduction of recurrent DVT and PE risk
• Prophylaxis of DVT following hip or knee replacement surgery

Off-label use, such as anticoagulation for antiphospholipid syndrome with triple-positive antibodies, may face denial. The American Society of Hematology 2023 guidelines note that direct oral anticoagulants are not recommended for that specific high-risk triple-positive population, which gives insurers clinical grounds to restrict coverage in that setting [5].

How Network Health Formularies Are Structured

Network Health is a regional Wisconsin-based insurer offering commercial, Medicaid, and Medicare Advantage plans. Each plan year brings a new formulary document, and Eliquis placement can shift between plan years.

Tier System Explained

Network Health uses a tiered formulary common to most US commercial insurers:

• Tier 1: Generic preferred drugs, lowest cost-sharing
• Tier 2: Generic non-preferred or lower-cost brands
• Tier 3: Preferred brand-name drugs
• Tier 4: Non-preferred brand-name drugs
• Tier 5: Specialty drugs

Eliquis most commonly lands on Tier 3 or Tier 4 on Network Health commercial plans, meaning a typical copay ranges from $45 to $100 per fill without assistance. On Medicare Advantage Part D formularies, Eliquis often appears at Tier 4 or Tier 5, where cost-sharing is calculated as a percentage (coinsurance) rather than a flat copay, sometimes reaching $150, $250 per month during the coverage gap.

How to Find Your Exact Tier

The most reliable way to confirm current placement is to use Network Health's online formulary search tool at networkhealth.com. You will need your plan name (found on your insurance card), the drug name "apixaban" or "Eliquis," and the dose (2.5 mg or 5 mg tablets). Formularies update every January 1, so always recheck at the start of a new plan year.

Your pharmacist can also run a test claim before you arrive for pickup, which will show the exact adjudicated cost under your current benefit.

Prior Authorization Requirements for Eliquis

Most Network Health plans require prior authorization (PA) before they will pay for Eliquis. The PA process is not a denial. It is a clinical review designed to confirm the prescription matches an approved indication and that cheaper alternatives have been considered.

What Information the PA Request Needs

Your prescribing clinician's office submits the PA. The typical documentation package includes:

• Diagnosis code (e.g., I48.0 for paroxysmal atrial fibrillation)
• Clinical notes confirming the diagnosis
• CHA2DS2-VASc score for atrial fibrillation patients (the ACC/AHA guideline recommends anticoagulation when the score is 2 or higher in men and 3 or higher in women) [4]
• Evidence of a contraindication or intolerance to warfarin if step therapy applies
• Recent INR records if the patient was previously on warfarin

The FDA's prescribing information for Eliquis lists contraindications including active pathological bleeding and severe hypersensitivity to apixaban [1]. Documenting these clearly speeds approval.

Step Therapy and How to Overcome It

Step therapy requires that a patient try a less-expensive drug first. For Eliquis, the typical step is warfarin or, in some plans, rivaroxaban (Xarelto). Network Health must accept clinical justification for bypassing step therapy if the patient has:

• Documented labile INR on warfarin (time in therapeutic range below 60%)
• Drug-drug interactions that make warfarin management difficult
• Patient-specific factors (e.g., frequent travel making INR monitoring impractical)
• Prior adverse event on the step-therapy drug

Wisconsin state law aligns with the majority of US states in allowing step-therapy exceptions when medically appropriate. The prescriber submits a step-therapy exception request alongside the PA, supported by chart notes.

PA Approval Timelines

Under federal regulations, commercial plans must respond to standard PA requests within 72 hours for urgent cases and 30 calendar days for non-urgent requests [6]. If Network Health does not respond within those windows, that failure itself can be grounds for an expedited appeal.

What Eliquis Costs on Network Health Plans

Cost depends on three variables: your tier, your deductible status, and whether you are using a copay card.

Commercial Plan Cost Scenarios

Before meeting your deductible, most commercial plans apply full negotiated cost to Eliquis, which may be $300, $500 per 30-day fill. After the deductible, the tier-based copay applies.

A Tier 3 placement with a $60 copay per fill means $720 per year in drug costs after deductible. A Tier 4 placement at $100 per fill means $1,200 per year. These numbers assume monthly fills; using 90-day supply fills at mail order typically reduces the per-fill cost by 10 to 20%.

Medicare Part D Cost Scenarios

Medicare Part D plans follow a standard benefit structure that the Centers for Medicare and Medicaid Services updates annually [7]. For 2025, the catastrophic coverage threshold changed significantly under the Inflation Reduction Act, capping out-of-pocket costs at $2,000 for the year across all Part D enrollees [8]. That cap meaningfully protects patients who previously paid thousands of dollars annually for Eliquis during the coverage gap.

Patients with low income may qualify for the Extra Help (Low Income Subsidy) program, which can reduce Eliquis copays to under $12 per month on Part D plans [7].

Medicaid Coverage

Network Health administers Medicaid plans in Wisconsin. Wisconsin Medicaid's preferred drug list generally includes at least one direct oral anticoagulant. Eliquis may require PA on the Medicaid formulary, but copays for Medicaid enrollees are nominal or zero for most income levels.

How to Reduce Your Eliquis Cost

Cost reduction strategies layer on top of each other. Using all available tools simultaneously produces the greatest savings.

The Bristol Myers Squibb / Pfizer Copay Card

Bristol Myers Squibb and Pfizer co-market Eliquis and offer an assistance card for commercially insured patients. Eligible patients pay as little as $10 per month, with the card covering up to $6,400 per calendar year [9]. The card is not available to Medicare, Medicaid, or any government-funded insurance beneficiaries.

To enroll: visit eliquis.bmscustomerconnect.com or call 1-855-ELIQUIS. Enrollment takes about five minutes, and the card can be used immediately at most pharmacies.

Patient Assistance Program for Uninsured or Medicare Patients

BMS's patient assistance program provides free Eliquis to uninsured patients and Medicare patients who meet income thresholds. Applications are available through the NeedyMeds database or directly through BMS [10]. Income limits are typically set at 400% of the federal poverty level or below, though BMS reviews cases individually.

Generic Alternatives and Therapeutic Substitution

No FDA-approved generic apixaban exists in the United States as of 2025 [2]. Rivaroxaban (Xarelto) and dabigatran (Pradaxa) are the closest alternatives in the direct oral anticoagulant class and may sit on a lower tier on Network Health plans. Warfarin remains a Tier 1 generic option but requires frequent INR monitoring.

Any switch from Eliquis to another anticoagulant must be managed by the prescribing clinician. The American Heart Association notes that all FDA-approved NOACs have comparable efficacy profiles for atrial fibrillation stroke prevention, though individual patient factors influence selection [4]. A clinician-directed therapeutic substitution, documented in the chart, can satisfy step-therapy requirements and allow Network Health to approve coverage for the preferred agent.

HealthRX Cost-Access Decision Framework for Eliquis on Network Health

Use this sequence when a patient faces coverage barriers:

1. Confirm current formulary tier via networkhealth.com drug search.
2. If PA required, submit immediately with CHA2DS2-VASc score, diagnosis codes, and INR history.
3. If step therapy applies, document warfarin contraindication or prior failure in writing.
4. Apply for BMS copay card if commercially insured (saves up to $6,400/year).
5. If Medicare, check Extra Help eligibility and note the $2,000 annual out-of-pocket cap for 2025.
6. If denied, file a formal appeal within the insurer's stated window (typically 60 to 180 days from denial date).
7. Request peer-to-peer review between Network Health's medical director and the prescribing cardiologist or hematologist.
8. If internal appeal fails, pursue external independent review, which Wisconsin law mandates must be completed within 45 days for standard appeals.

Filing an Appeal When Network Health Denies Eliquis

Denials happen. They are not final. Federal law under the Affordable Care Act requires all non-grandfathered health plans to offer at least one internal appeal and access to external review [11].

Internal Appeal

The prescriber or patient submits a written appeal with supporting clinical documentation. Attach the denial letter, the original PA submission, peer-reviewed literature supporting Eliquis use for the specific indication, and any specialist letters. The ARISTOTLE trial data [3] and the ACC/AHA atrial fibrillation guideline [4] are appropriate supporting references.

External Independent Review

If the internal appeal fails, Wisconsin residents can request external review through the Wisconsin Office of the Commissioner of Insurance. An independent review organization, not affiliated with Network Health, makes a binding decision. For life-threatening conditions, expedited external review must be completed within 72 hours under federal law [11].

Expedited Appeals for Urgent Situations

If a delay would seriously jeopardize health or ability to function, the prescriber can request an expedited appeal. Network Health must respond within 72 hours. Document clinical urgency explicitly in the request, for example: "Patient has CHA2DS2-VASc score of 5 and is at high near-term stroke risk without anticoagulation."

Clinical Context: Why Eliquis Is Prescribed Instead of Cheaper Options

Understanding why a prescriber chose Eliquis over warfarin helps build a stronger PA and appeal case.

Evidence Basis for Apixaban

The ARISTOTLE trial demonstrated that apixaban reduced all-cause mortality by 11% relative to warfarin (3.52% vs. 3.94% per year; P=0.047), along with fewer major bleeding events (2.13% vs. 2.92% per year; P<0.001) [3]. The AMPLIFY trial (N=5,395) showed that apixaban was non-inferior to enoxaparin plus warfarin for acute DVT/PE treatment, with significantly fewer major bleeding events (0.6% vs. 1.8%; P<0.001) [12]. These two trials form the primary evidence base cited in most PA justification letters.

Warfarin's Practical Limitations

Warfarin requires regular INR monitoring, interacts with dozens of medications and foods, and has a narrow therapeutic window. The FDA's prescribing information for warfarin lists over 200 known drug interactions [13]. Patients with labile INR, polypharmacy, or limited access to monitoring labs are reasonable candidates for an alternative. Documenting these factors explicitly turns step-therapy objections into approvals.

Renal Dosing Considerations

Apixaban is dose-reduced to 2.5 mg twice daily when a patient meets two of three criteria: age 80 or older, weight 60 kg or under, or serum creatinine 1.5 mg/dL or higher [1]. Dabigatran, a competing direct oral anticoagulant, is contraindicated when creatinine clearance falls below 15 mL/min [14]. For patients with moderate chronic kidney disease, apixaban's pharmacokinetic profile may make it the preferred agent, which is a clinically valid justification for bypassing step therapy to a renally-cleared alternative.

What to Do Right Now

Confirm your plan's current Eliquis formulary status before your next refill. If you have a commercial Network Health plan and are not yet using the BMS copay card, enroll today; eligible patients have paid full price unnecessarily. If you are on Medicare, check whether your Part D plan's $2,000 out-of-pocket cap for 2025 changes your cost calculation, and ask your pharmacist to confirm which fill month you will hit that cap.

If your PA has been denied in the past 180 days, it may still be appealable. Contact Network Health's member services line (on the back of your insurance card) to ask about the appeal deadline and request the denial rationale in writing.

A cardiologist's or internist's office can submit a peer-to-peer request directly to Network Health's pharmacy director. That single phone call resolves a high proportion of PA denials for Eliquis before a formal appeal is needed.